The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin.
Norfloxacin, a new quinolone compound has marked activity against strains of Pseudomonas aeruginosa being superior to that of gentamicin, carbenicillin, ticarcillin, the ureidopenicillins and cephalosporins, and similar to that of tobramycin. Nineteen patients with complicated urinary tract infections caused by Pseudomonas spp. were treated with norfloxacin and 16 (84%) responded to therapy. No side or toxic effects were seen. Two of the three failures of treatment were due to underlying uripenicillins and cephalosporins, and similar to that of tobramycin. Nineteen patients with complicated urinary tract infections caused by Pseudomonas spp. were treated with norfloxacin and 16 (84%) responded to therapy. No side or toxic effects were seen. Two of the three failures of treatment were due to underlying uripenicillins and cephalosporins, and similar to that of tobramycin. Nineteen patients with complicated urinary tract infections caused by Pseudomonas spp. were treated with norfloxacin and 16 (84%) responded to therapy. No side or toxic effects were seen. Two of the three failures of treatment were due to underlying urinary tract disease. The other failure was due to a resistant strain of Ps. aeruginosa. Norfloxacin is a new valuable oral antimicrobial agent with a wide range of bacterial activity which includes many strains of bacteria resistant to other agents. Due to its high urinary concentrations, norfloxacin is particularly indicated in the treatment of urinary tract infections.